Literature DB >> 17545348

Risk assessment in diabetes management: how do general practitioners estimate risks due to diabetes?

Bertram Häussler1, Gisela C Fischer, Sibylle Meyer, Diethard Sturm.   

Abstract

OBJECTIVES: To evaluate the ability of general practitioners (GPs) in Germany to estimate the risk of patients with diabetes developing complications.
METHODS: An interview study using a structured questionnaire to estimate risks of four case vignettes having diabetes-specific complications within the next 10 years, risk reduction and life expectancy potential. A representative random sample of 584 GPs has been drawn, of which 150 could be interviewed. We compared GPs' estimates among each other (intraclass correlation coefficient (ICC) and Cohen's (multirater-) kappa) and with risks for long-term complications generated by the multifactor disease model "Mellibase", which is a knowledge-based support system for medical decision management.
RESULTS: The risk estimates by GPs varied widely (ICC 0.21 95% CI (0.13 to 0.36)). The average level of potential risk reduction was between 47% and 70%. Compared with Mellibase values, on average, the GPs overestimated the risk threefold. Mean estimates of potential prolongation of life expectancy were close to 10 years for each patient, whereas the Mellibase calculations ranged from 3 to 10 years.
CONCLUSIONS: Overestimation could lead to unnecessary care and waste of resources.

Entities:  

Mesh:

Year:  2007        PMID: 17545348      PMCID: PMC2464989          DOI: 10.1136/qshc.2006.019539

Source DB:  PubMed          Journal:  Qual Saf Health Care        ISSN: 1475-3898


  17 in total

Review 1.  Personalised risk communication for informed decision making about entering screening programs.

Authors:  A Edwards; S Unigwe; G Elwyn; K Hood
Journal:  Cochrane Database Syst Rev       Date:  2003

2.  [National guideline for diabetes mellitus type 2, abridged version. May 2002. Federal Chamber of Physicians].

Authors: 
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2002-07

3.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

Review 4.  Testing four competing theories of health-protective behavior.

Authors:  N D Weinstein
Journal:  Health Psychol       Date:  1993-07       Impact factor: 4.267

5.  Risk and potential risk reduction in diabetes type 2 patients in Germany.

Authors:  Bertram Häussler; Ursula Berger; Oliver Mast; Wolfgang Thefeld
Journal:  Eur J Health Econ       Date:  2005-06

6.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

Authors: 
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

7.  Health beliefs, compliance, and control of diabetes mellitus.

Authors:  R Harris; M W Linn
Journal:  South Med J       Date:  1985-02       Impact factor: 0.954

8.  When there is too much to do: how practicing physicians prioritize among recommended interventions.

Authors:  Timothy P Hofer; Judith K Zemencuk; Rodney A Hayward
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

9.  Risk perception for developing diabetes: comparative risk judgments of physicians.

Authors:  Elizabeth A Walker; C K Mertz; Maria R Kalten; James Flynn
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

Review 10.  Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Authors:  Kurt Neeser; Georg Lübben; Uwe Siebert; Wendelin Schramm
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more
  1 in total

1.  International challenges without borders: a descriptive study of family physicians' educational needs in the field of diabetes.

Authors:  Suzanne Murray; Patrice Lazure; Sara Schroter; Philipp J Leuschner; Peter Posel; Thomas Kellner; Richard D Jenkins
Journal:  BMC Fam Pract       Date:  2011-05-11       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.